Takenaka T, Ohno Y, Suzuki H. Impacts of sodium-glucose co-transporter type 2 inhibitors on central blood pressure.
Diab Vasc Dis Res 2018;
15:154-157. [PMID:
29168387 DOI:
10.1177/1479164117742317]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AIMS
To assess the effects of sodium-glucose co-transporter type 2 inhibitors on central blood pressure, an important determinant of cardiovascular events.
METHODS
Canagliflozin, Empagliflozin or Luseogliflozin was given for 102 type 2 diabetic patients with hypertension and nephropathy. Central blood pressure was evaluated by radial tonometry. Clinical parameters were followed for 6 months.
RESULTS
Three differing sodium-glucose co-transporter type 2 inhibitors similarly reduced brachial and central blood pressures, casual blood sugar, haemoglobin A1c, estimated glomerular filtration rate and albuminuria without significant changes in pulse rate and lipid profiles. Central systolic blood pressure was associated with the decreases in albuminuria by sodium-glucose co-transporter type 2 inhibitors.
CONCLUSION
Comparable influences of various sodium-glucose co-transporter type 2 inhibitors on central blood pressure suggest class effects.
Collapse